MANF is a potent neurotrophic factor which is used to treat apoptosis-related diseases including Parkinson’s disease.
Amarantus claims to protect its compositions of matter and methods of use for MANF, and other related compounds in the patent.
Amarantus BioSciences CEO Martin Cleary said the new patent will further protect its intellectual property as the company expands its pipeline of first-in-class therapeutics to address a number of indications.
The company said MANF is currently in pre-clinical development.